Kineta is an emerging biotech company that is dedicated to advancing novel immuno-therapies from discovery to proof of concept. With a focus on innate immunity, Kineta aims to develop next-generation immunotherapies that can transform the lives of patients. Unlike other immuno-oncology companies that primarily focus on adaptive immunity and T cell therapies, Kineta has established an Innate Immunity Development Platform.

This platform is designed to develop fully human antibodies that address the major mechanisms of cancer immune resistance. With drug candidates expected to enter clinical trials and a strong intellectual property position, Kineta is poised to achieve multiple value-driving catalysts. The company boasts an experienced management team, a talented research and development team, a renowned scientific advisory board, and a leading position in immuno-oncology.

Kineta's mission is to develop potentially differentiated immunotherapies that address the major challenges of current cancer therapy and provide new hope for cancer patients